Articles tagged "Liver transplantation"

2016 American Transplant Congress
Live Donor Liver Transplantation for NASH: The Toronto Experience.
A. Barbas, N. Goldaracena, M. Dib, M. Marquez, G. Sapisochin, D. Al-Adra, I. McGilvray, M. Cattral, P. Greig, D. Grant.
General Surgery, Multi-Organ Transplant, University of Toronto, Toronto, ON, Canada.
Background:Non-alcoholic steatohepatitis (NASH) is an increasingly common indication for liver transplantation in North America. In the context of organ scarcity and significant waitlist mortality, our…
2016 American Transplant Congress
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.
S. Prenner, L. VanWagner, L. Kulik.
Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
Background: The efficacy of direct acting antiviral agents (DAA) for hepatitis C (HCV) in patients with hepatocellular carcinoma (HCC) is limited. We hypothesized that virology…
2016 American Transplant Congress
Experience Using a Discharge Calculator for Discharge Planning Post Liver Transplantation (OLT).
K. Kerepesi, A. Waby, K. Eid, J. Plescia, K. Zinn, K. Vass, B. Eghtesad, C. Miller, D. Kelly.
Cleveland Clinic, Cleveland, OH.
We previously developed and validated a nomogram to predict discharge disposition post OLT. The current study analyzes our experience using the discharge calculator.Patients &Methods:We retrospectively…
2016 American Transplant Congress
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.
F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
¹Hôpital Paul Brousse, Villejuif, France; ²Hôpital Henri Mondor, Créteil, France; ³Hôpital Claude Huriez, Lille, France; ⁴Hôpital Edouard Herriot, Lyon, France; ⁵Hôpital La Pitié-Salpêtrière, Paris, France; ⁶Novartis Pharma SAS, Rueil-Malmaison, France.
Introduction: Long-term post-liver transplant (LTx) complications, particularly impaired renal function (RF) and its consequences, remain a concern. Presented here are the results of the SIMCER…
2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
2016 American Transplant Congress
Portal Vein Complication After Living Donor Right Hepatectomy.
D.-H. Jung, S.-G. Lee, S. Hwang, K.-H. Kim, C.-S. Ahn, D.-B. Moon, T.-Y. Ha, G.-W. Song, W.-J. Kim, S.-H. Kim, W.-H. Kang, J.-H. Kwon, E.-K. Jwa, H.-D. Cho.
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
BackgroundLiving donor hepatectomy may carry a significant risk of morbidity and mortality for the otherwise healthy donor. Portal vein (PV) complication after donor hepatectomy is…
2016 American Transplant Congress
Effect of Modifying Life Support Withdrawal Practices on Outcomes of Donation After Circulatory Death in Liver Transplantation: A Meta-Analysis.
Y. Cao,^1,2 S. Shahrestani,³ H. Chew,^2,4 M. Crawford,⁵ P. Macdonald,^1,2,4 J. Laurence,^3,5,7 W. Hawthorne,^3,6 K. Dhital,^1,2,4 H. Pleass.^3,5,6
¹Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; ²Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; ³Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁴Cardiac Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ⁵Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia; ⁶The Department of Surgery, Westmead Hospital, Sydney, NSW, Australia; ⁷Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Aim. Donor warm ischaemic time is identified as the main risk factor for poor outcomes in liver transplantation using donation after circulatory death (DCD) compared…
2016 American Transplant Congress
The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.
J. Moore, X. Luo, A. Massie, T. Purnell, D. Mogul, D. Segev.
Johns Hopkins School of Medicine, Baltimore.
Past studies have shown inferior liver graft survival in gender-discordant recipient/donor pairings compared to gender-matched pairings, particularly in male recipients of female donor livers. However,…
2016 American Transplant Congress
LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions.
A. Masoumi,¹ R. Barth,² J. LaMattina,² D. Bruno,² L. Hebert,¹ N. Schluterman,³ S. Hanish.²
¹University of Maryland Medical Center, Baltimore, MD; ²Department of Surgery, University of Maryland School of Medicine, Baltimore, MD; ³Department of Epidemiology, University of Maryland School of Public Health, Baltimore, MD.
Background:One-fifth of Medicare patients are readmitted to the hospital an annual cost of $17.4 billion. The LACE Index (Length of stay, Acuity of the admission,…
2016 American Transplant Congress
Outcomes of Arterial and Venous Conduits for Vessel Reconstruction in Liver Transplantation.
J. Tan,¹ G. Oniscu.²
¹University of Edinburgh, Edinburgh, United Kingdom; ²Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Background: The use of hepatic artery (HA) and portal vein (PV) conduits is a recognised alternative technique in vessel reconstruction during liver transplantation. The hepatic…